List view / Grid view
27 February 2017 | By Niamh Marriott, Digital Editor
The EMA approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with non-small cell lung cancer...
7 February 2017 | By Niamh Marriott, Digital Editor
Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in…
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Novartis' two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo...
6 December 2016 | By Niamh Louise Marriott, Digital Editor
Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%...
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries...
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The US Food and Drug Administration (FDA) accepted Novartis’ new drug application (NDA) for filing and granted priority review for LEE011 (ribociclib)...
31 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Novartis has been awarded the 2016 Prix Galien USA Award "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec, as well as...
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy...
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The aim of Novartis' plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness...
